皓元医药：公司2025年1-6月计提资产及信用减值损失共计6620.09万元

Group 1 - The company, Haoyuan Pharmaceutical, announced a provision for asset and credit impairment losses totaling 66.2 million yuan for the first half of 2025, which will reduce the total profit by the same amount [1] - The net profit attributable to the parent company will decrease by 61.5 million yuan due to this provision [1] - The company's total equity will also be reduced by 61.5 million yuan for the same period [1] Group 2 - For the year 2024, Haoyuan Pharmaceutical's revenue composition indicates that 99.27% comes from research and experimental development, while other businesses account for only 0.73% [1] - The company's market capitalization is currently 12.8 billion yuan [2]